Review article · 2012
Mini reviewPublished 30 Jun 2023
Scleroderma: Pathogenesis, Clinical Features, and Management
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Scleroderma, also known as systemic sclerosis, is a complex autoimmune disorder characterized by progressive fibrosis and vascular abnormalities affecting multiple organs. This abstract provides an overview of the pathogenesis, clinical features, and management strategies for scleroderma. The pathogenesis of scleroderma involves immune dysregulation, leading to excessive collagen deposition and fibrosis in the skin and internal organs. Genetic factors, environmental triggers, and aberrant immune responses contribute to the development of the disease. Dysregulated endothelial cell function and vascular damage further contribute to the pathogenesis, leading to tissue ischemia and organ dysfunction. Clinical manifestations of scleroderma are diverse and can affect the skin, gastrointestinal tract, lungs, heart, kidneys, and musculoskeletal system. The hallmark feature is skin fibrosis, which can range from localized involvement to widespread systemic sclerosis. Other common clinical features include Raynaud's phenomenon, digital ulcers, gastroesophageal reflux disease, interstitial lung disease, pulmonary arterial hypertension, renal crisis, and musculoskeletal pain. The management of scleroderma is multidisciplinary and tailored to the specific organ involvement and disease severity. Treatment goals include symptom control, prevention of complications, and preservation of organ function. Medications such as immunosuppressants, vasodilators, and antifibrotic agents may be used to target the underlying pathogenesis and manage specific manifestations. Physical and occupational therapy, along with lifestyle modifications, play an essential role in maintaining joint mobility, managing pain, and improving overall quality of life. The abstract concludes by highlighting the importance of early diagnosis, close monitoring, and collaborative care involving rheumatologists, dermatologists, pulmonologists, cardiologists, and other specialists. Further research is needed to elucidate the underlying mechanisms of scleroderma and develop targeted therapies to improve outcomes for affected individuals.
Subjects
RheumatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 27 Feb 2025
Antiphospholipid Syndrome (APS): Pathogenesis, Clinical Features, and Management
Article · 29 Aug 2025
Lupus Nephritis: Pathogenesis, Clinical Features, and Evolving Therapies
Article · 28 Jun 2025
Inflammatory Arthritis: Pathophysiology, Clinical Features, and Management
Opinion · 7 Jul 2023
Clinical Features and Management Strategies of Hypophosphatasia
More from this journal
The newest in International Journal of Clinical Rheumatology.
Article · 27 Feb 2026
Ultrasound assessments of lower extremity joint structures from astronauts after 18 days on board the International Space Station
Article · 27 Feb 2026
Ultrasound assessments of lower extremity joint structures from astronauts after 18 days on board the International Space Station
Article · 30 Dec 2025
Genomics in Autoimmune Disease: Unraveling Genetic Contributions and Personalized Approaches
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Clinical Rheumatology
- SubjectRheumatology
- BylineArticles whose byline prints “Mikkel Ostergaard”
